Protagonist Therapeutics Inc (PTGX)
25.15
+0.49
(+1.99%)
USD |
NASDAQ |
Apr 26, 16:00
25.11
-0.04
(-0.16%)
After-Hours: 20:00
Protagonist Therapeutics Research and Development Expense (Quarterly): 28.90M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 28.90M |
| September 30, 2023 | 30.66M |
| June 30, 2023 | 33.18M |
| March 31, 2023 | 27.42M |
| December 31, 2022 | 29.88M |
| September 30, 2022 | 25.40M |
| June 30, 2022 | 34.61M |
| March 31, 2022 | 36.32M |
| December 31, 2021 | 38.37M |
| September 30, 2021 | 36.96M |
| June 30, 2021 | 26.43M |
| March 31, 2021 | 24.24M |
| December 31, 2020 | 19.49M |
| September 30, 2020 | 16.00M |
| June 30, 2020 | 20.26M |
| March 31, 2020 | 18.77M |
| December 31, 2019 | 15.91M |
| September 30, 2019 | 17.29M |
| Date | Value |
|---|---|
| June 30, 2019 | 19.36M |
| March 31, 2019 | 12.44M |
| December 31, 2018 | 14.25M |
| September 30, 2018 | 12.14M |
| June 30, 2018 | 17.74M |
| March 31, 2018 | 15.37M |
| December 31, 2017 | 11.72M |
| September 30, 2017 | 11.17M |
| June 30, 2017 | 12.01M |
| March 31, 2017 | 11.28M |
| December 31, 2016 | 8.823M |
| September 30, 2016 | 5.561M |
| June 30, 2016 | 5.696M |
| March 31, 2016 | 5.625M |
| December 31, 2015 | 4.193M |
| September 30, 2015 | 3.158M |
| June 30, 2015 | 2.297M |
| March 31, 2015 | 2.183M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.91M
Minimum
Dec 2019
38.37M
Maximum
Dec 2021
26.29M
Average
26.43M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| SELLAS Life Sciences Group Inc | 5.097M |
| Arvinas Inc | 95.20M |
| Akebia Therapeutics Inc | 9.865M |
| Immuneering Corp | 11.91M |
| Moderna Inc | 1.406B |